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Abstract
Objectives: The HEPAIG study was conducted to better understand Hepatitis C virus (HCV) transmission among human
immuno-deficiency (HIV)-infected men who have sex with men (MSM) and assess incidence of HCV infection among this
population in France.
Methods and Results: Acute HCV infection defined by anti-HCV or HCV ribonucleic acid (RNA) positivity within one year of
documented anti-HCV negativity was notified among HIV-infected MSM followed up in HIV/AIDS clinics from a nationwide
sampling frame. HIV and HCV infection characteristics, HCV potential exposures and sexual behaviour were collected by the
physicians and via self-administered questionnaires. Phylogenetic analysis of the HCV-NS5B region was conducted. HCV
incidence was 48/10 000 [95% Confidence Interval (CI):43–54] and 36/10 000 [95% CI: 30–42] in 2006 and 2007, respectively.
Among the 80 men enrolled (median age: 40 years), 55% were HIV-diagnosed before 2000, 56% had at least one sexually
transmitted infection in the year before HCV diagnosis; 55% were HCV-infected with genotype 4 (15 men in one 4d-cluster),
32.5% with genotype 1 (three 1a-clusters); five men were HCV re-infected; in the six-month preceding HCV diagnosis, 92%
reported having casual sexual partners sought online (75.5%) and at sex venues (79%), unprotected anal sex (90%) and
fisting (65%); using recreational drugs (62%) and bleeding during sex (55%).
Conclusions: This study emphasizes the role of multiple unprotected sexual practices and recreational drugs use during sex
in the HCV emergence in HIV-infected MSM. It becomes essential to adapt prevention strategies and inform HIV-infected
MSM with recent acute HCV infection on risk of re-infection and on risk-reduction strategies.
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Introduction
The overall prevalence of hepatitis C virus (HCV) infection in
HIV-infected individuals in France is estimated to be 24% ranging
from 93% of those who acquired HIV through injecting drug use
to 3% of men who acquired HIV through sexual contact with men
[1]. If sexual transmission of HCV is rarely reported among
monogamous heterosexual couples [2], outbreaks of acute
hepatitis C have been reported since 2000, in HIV-infected men
who have sex with men (MSM) who deny injecting drug use [3–5],
suggesting growing evidence of sexually transmitted HCV in this
population. Furthermore, several MSM cohort studies evaluating
risk factors associated with HIV transmission have observed an
increase in HCV incidence since 2000 among HIV-infected MSM
who were not injecting drug users [6–9]. Following the French
case reports [10,11], we conducted the prospective HEPAIG study
to better understand the transmission dynamics of HCV
emergence in HIV-infected MSM and to assess the incidence of
HCV infection in this population.
Methods
Ethics statement
The study conforms to the ethical guidelines of the 1975
Helsinki Declaration. The study protocol was approved by the
French data protection authority. The study’s protocol was
explained to all patients meeting the case definition who all
provided written consent when enrolled.
Study population
A sampling frame of 290 HIV/AIDS clinics was constructed
using the number of HIV/AIDS cases notified in MSM to the
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These clinics distributed throughout France were asked and
reminded to report : i) prospectively, each case of acute HCV
infection diagnosed in 2006 and 2007 in MSM followed up for
HIV infection; ii) at the end of each year during the study period,
the total number of cases even in the absence of case.
Acute HCV infection was defined as: 1) a confirmed case when
anti-HCV were detected within one year after a documented anti-
HCV negativity or when HCV Ribonucleic Acid (RNA) was
detected within one year after documented anti-HCV and HCV
RNA negativity; 2) a possible case when HCV RNA was detected
either: i) within one year after two consecutive documented HCV
RNA negatives by PCR; or ii) following clinical signs of hepatitis
and alanine aminotransferase (ALT) level over 10 times the upper
limit of normal (ULN) within one year after regular controls of
normal ALT levels (other causes of acute hepatitis being excluded).
All cases were confirmed anti-HCV positive.
Acute HCV re-infection was defined as having detectable HCV
RNA following at least two documented undetectable HCV RNA
within one year after spontaneous viral clearance (in the absence of
anti-HCV treatment) [12] or following at least 24 weeks after the
end of anti-HCV treatment [13]. HCV re-infection was confirmed
when change in HCV genotype compared with primary infection
was observed, otherwise, re-infection was probable.
Data collection
Two paper-based forms were completed after consent: i) the
medical questionnaire completed by the physicians according to
the patient responses and from the medical record, collected
reasons for HCV screening and data on HIV and HCV infection
characteristics, sexually transmitted infections (STI) and potential
at-risk exposures (drug use, tattoo/piercing, medical invasive
procedures, unprotected sex) within the twelve months before
acute HCV infection diagnosis; ii) the self-administered question-
naire, completed secondarily (e.g. at home) by the patient and
returned by post to the main investigator. With 68 wide-ranging
questions, this questionnaire collected data on socio-demographic
characteristics, social and sexual life. Specifically, questions were
focused on the six-month period before HCV diagnosis and
assessed medication consumptions, snorting or injecting drug use,
history of sexually transmitted infection (STI) and sexual
behaviour with the regular and casual partners (if any) including
number of male sexual partners, type of sexual practices (e.g.
unprotected sex, fisting, bondage, discipline, sadism, masochism
(BDSM), drug use during sex including type of drug and mode of
administration) and sex venues attendance.
HCV RNA detection and HCV genotyping were carried out in
routine by the clinics’ laboratories during the study period. These
laboratories used commercially available HCV RNA assays (based
on real-time Polymerase Chain Reaction (PCR) technology) and
for genotyping the same standardized assays based on reverse
hybridisation technology (Inno-LiPA) or direct sequencing (based
on real-time PCR technology). Of note, these laboratories were
involved in the French panel quality control study [14].
For men who declined to participate, dates of HIV and HCV
diagnosis, age at HCV diagnosis, and region of care were collected.
Phylogenetic analysis
After patient consent, the first-RNA-positive plasma sample
available after the diagnosis of acute HCV infection C was
centralized in the HEPAIG reference laboratory and stored at
280uC. HCV RNA was extracted using the Qiamp viral RNA
method (Qiagen, Courtaboeuf, France). The primers used for the
HCV-NS5B amplification were: outer primers (S0 755:
59-TATGAYACCCGCTGYTTTGACTC-39; ASO 1121: 59-
GCNGARTAYCTVGTCATAGCCTC-39) and inner primers
(S0 755: 59-TATGAYACCCGCTGYTTTGACTC-39; ENO2:
59-GCTAGTCATAGCCTCCGT-39) for the hemi-nested PCR.
Primers were designed to amplify a 382 bp c-DNA fragment of
NS5b. After purification of the PCR products, direct sequencing
was performed as previously described [11]. All sequences were
aligned with Clustal X 2.0.11 H software. Pairwise evolutionary
distances were estimated with DNADist, using Kimura’s two-
parameter method, then the phylogenetic trees were constructed
by a neighbour joining method (neighbour program implemented
in the Phylip package) [15]. The reliability of each tree topology
was estimated from 1000 bootstrap replicates [15].
Reference sequences used for comparison were retrieved from
the Los Alamos HCV Database (6bD84262, 7bD84263,
6aY12083, 11aD63822, 8bD84264, 9aD84265, 3aD17763,
3aD28917, 10aD63821, 3bD49374, 4aY11604, 1aM62321,
1aM67463, 1g_Egypt, 1bM58335, 1bU45476, 1bD13558,
1cD14853, 5aAF064490, 5aY13184, 2bD10988, 2cD50409,
2aD00944, 1a004102, 3a.AF046866 , 3a.D28917, 3a.009824)
(http://hcv.lanl.gov). Eleven local NS5B genotype 4d sequences
from French patients were added: FrSSD41, FrSSD85, FrSSD58,
FrSSD37, FrSSD65, FrSSD50, FrSSD171, FrSSD163,
FrSSD164, MRS95, P9_RCP, 7 of them were identified in IVDU
(FrSSD41, FrSSD171, FrSSD085, FrSSD092, FrSSD163,
FrSSD164, FrDSS050). Additional sequences of genotypes 1a
and 3a were also included in the analyses (four genotype 1a
sequences from French patients (AJ231494, AJ231491, FrSSD54,
FrSSD27), 1.AJ851228, 1a.EU155345 to 1a.EU155349, 1a.
EU482853, 3a.GQ332555 to 3a.GQ332557, 3a.X76918).
Sequences reported in this study (n=32) have been submitted to
GenBank and can be retrieved under accession numbers JF964963
to JF964994.
The HCV genotyping results taken into account for the purpose
of the analysis were all of those from the HEPAIG reference
laboratory and, if not available, those from the clinic’ laboratories.
Statistical analysis
Individuals included in the sample were considered to have
been randomly sampled by a two-stage cluster design. An inclusion
probability was calculated for each individual, equals to the
inclusion probability of the participating clinic. Then sampling
weights were calculated equal to the inverse of the inclusion
probabilities. HCV incidences were estimated using the Horvitz-
Thompson estimator including sampling weights and widely used
in the classical sampling literature. Estimates were improved by a
post-stratification technique using census data (number of HIV-
infected MSM followed up annually in each clinic, by year).
Estimated variances associated to HCV incidence estimates were
also calculated. Assuming a normal distribution for incidence
estimates, 95% confidence intervals (CI) were then computed. To
estimate HCV incidence, the estimated number of acute HCV
infection cases was divided by the total number of HIV-infected
MSM followed up annually in the participating clinics. Data were
analyzed using STATAH 11.0 (StataCorp, College Station, TX).
Fisher’s exact test, x
2 test, Student’s t test and Wilcoxon’s test were
used. Values of P value,0.05 were considered statistically
significant.
Results
Incidence of HCV infection in HIV-infected MSM
In 2006 and 2007, respectively, 99 and 96 clinics that notified
80% of the new AIDS diagnosis in MSM in France in 2003
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MSM (64% in the Parisian region). This corresponds to an
estimated number of 110 and 87 cases, and to an estimated HCV
incidence of 48/10 000 [95% CI: 43–54] in 2006 and, 36/10 000
[95% CI: 30–42] in 2007.
Patient clinical characteristics
Of the 102 MSM with acute HCV infection, 80 agreed to
participate. Compared with the participants, the nonparticipants
were older at HCV diagnosis (mean age: 44.0 years versus 40.8
years; P=0.03), but did not differ according to region of care, year
of HCV diagnosis, and time between HIV and HCV diagnosis.
Of the 80 men who agreed to participate, 48 (60.0%) sought
care in the Parisian region (Table 1). Median age at HCV
diagnosis was 40 years (inter-quartile range (IQR): 36–44). At the
time of the acute HCV infection diagnosis, 44 men (55.0%) were
HIV diagnosed before 2000, 8 men (10.0%) had a previous
diagnosis of AIDS-defining illness, 14 (17.5%) had CD4 cell counts
below 350/mm3 and 24 (30.0%) had no antiretroviral treatment.
HCV infection was diagnosed because of an elevated ALT level in
62 men (77.5%) with concomitant diagnosis of STI in 29 MSM
(syphilis in 20; Chlamydia rectal infection in 8; gonorrhea in one).
At the time of diagnosis or in the year before HCV diagnosis
(medical questionnaires), overall, 45 men (56.2%) had at least one
STI (syphilis for 34 men) and, 22 (27.5%) had not (no information:
13 men) (Table 2). Regarding information on potential exposures
to HCV in the year prior HCV diagnosis collected by the
physicians, no exposure was reported for 60% of the MSM and
snorting drug use but no injecting for 26% (Table 2),
Acute HCV infection was confirmed in 59 MSM (74.0%) and
possible in 21 (including re-infection in 5). Jaundice was reported
for 9 men (11.2%) (Table1). ALT level was normal in six MSM
and HCV viral load was below 5.9 log10 IU/mL in 39 men
(48.8%). HCV genotypes were mainly genotype 4 (55.0%) and 1
(32.5%), but this distribution was different between 2006 and
2007, genotype 4 decreasing from 70.7% [95%CI=59.6279.8]
to 38.5% [95%CI=28.2249.8] (P=0.004), and genotype 1
increasing from 19.5% [95%CI=12.1229.9] to 46.1%
[95%CI=35.3257.4] (P=0.01).
Potential exposures reported by the participants (self-
administered questionnaire)
Fifty three men (66%) returned the confidential self-adminis-
tered questionnaire. When comparing their medical question-
naires, the 27 who did not complete the self-administered
questionnaire presented similar socio-demographics, HIV and
HCV infection characteristics, and history of STIs and of potential
HCV exposures. Among these 53 MSM, the median number of
sexual partners was 20 (IQR: 10–30) in the six months before
HCV diagnosis, 40 men (75.5%) sought their partners online, and
42 (79.2%) at sex venues. Among the 27 men (50.9%) who had a
regular sexual male partner, 26 reported having sex in group in
the six months before acute HCV infection. Overall, 49 men
(92.4%) reported having sex with casual sexual partners who were
HIV-infected in 81.6%. Sexual practices with casual partners were
predominantly unprotected (Table 3) and included fisting in 35
(71.5%), BDSM in 26 (58.1%) and, bleeding during sex was
reported by 26 men (58.1%). In the six months before HCV
diagnosis, 28 men (52.8%) were on psychiatric medications
including antidepressant for 8 (Table 4).
Injecting use of cocaine (with sharing syringes) was reported by
one patient G1-infected. During sex, poppers (amyl nitrite) were
used by 47 men (88.7%) and other recreational drugs (including:
marijuana, ecstasy, cocaine, c-hydroxybutyric acid (GHB),
ketamine, and methamphetamine) by 33 (62.3%). At least two
different recreational drugs (not including marijuana and poppers)
were consumed during sexual practices by 24 men (45.3%). Of the
21 MSM who reported snorting cocaine during sex, 16 reported
sharing straws. Intra-rectal use of recreational drugs was reported
by nine men, six of whom were G1-infected. Overall, four men
(7.5%) reported neither recreational drug use (besides marijuana
or amyl nitrite), nor bleeding during sex or fisting or BDSM. For
three of these men no STI was diagnosed in the year before HCV
diagnosis.
Phylogenetic analysis
No difference was found in terms of socio-demographics or
characteristics of HIV and HCV infection between the 32 men
with available frozen plasma samples included in the phylogenetic
analysis and the others. HCV subtypes 1a (14, 43.7%) and 4d (16,
50.0%) were predominant and, HCV subtypes 3a and 4a each
infected one MSM. The phylogenic tree of NS5B sequences
showed four clusters: three clusters of subtype 1a (cluster I-III) and
one cluster of subtype 4d (cluster IV) with monophyletic 4d
sequences from MSM clearly distinct from 4d sequences obtained
in French injecting drug users. Similarly, the three clusters of
subtype 1a (cluster I-III) are monophyletic and no other sequences
of genotype 1a (including sequences from French patients) were
included in the three clusters (Figure 1).
Several potential HCV exposures were shared between the
fifteen MSM in cluster 4d-IV: at least one STI in the year
preceding HCV was diagnosed in ten, eight reported at least one
recreational drug use during sex (ecstasy, cocaine, ketamine or
GHB) but none reported methamphetamine use and six reported
fisting. The MSM of clusters 1a shared sex venues attendance and
bleeding during sex (cluster 1a-I and 1a-III) or sex venues
attendance and fisting (cluster 1a-II).
HCV re-infections
Acute re-infection was diagnosed and confirmed in five MSM.
The first HCV infection was diagnosed after 2000 and after HIV
diagnosis in four. All but one were infected secondarily with HCV
genotype 4, all being primarily infected with another genotype
(unknown for one who cleared HCV spontaneously after cardiac
surgery in childhood). No potential HCV exposure was found for
one patient, two had at least one STI in the six months preceding
re-infection, two reported unprotected fisting, one reported
bleeding during sex and one snorted drugs.
Discussion
Incidence
The HEPAIG study, based on a nationwide sampling of
infectious diseases and internal medicine departments caring for
HIV-infected patients, provides estimates of the incidence of acute
HCV infection in the population of HIV-positive MSM in France.
HCV incidence estimates were below 0.5% and remained stable
between 2006 and 2007. Since 2002, the French expert group for
medical management of HIV infection has recommended that
HCV screening be repeated periodically, particularly for patients
reporting injecting drug use. After the first reports of HCV
outbreaks in HIV-positive MSM described in 2004 [10,16], HCV
screening at least once a year has been strongly encouraged for
HIV-infected MSM. The median level of ALT at diagnosis and
proportion of jaundice in our study (11%) were as expected for
HIV-positive individuals with recently acquired HCV infection
[17]. These estimates are similar when compared to the two
European MSM cohort estimates [8,9] calculated retrospectively
Acute Hepatitis C in HIV-Infected MSM
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injecting drug use, but three times lower than the estimate found in
2006 among HIV-infected MSM attending a public sexual health
clinic in England [18]. However, our estimates could be
underestimated: i) superinfections (i.e. subsequent infection with
a heterologous HCV strain in the presence of a previous HCV
Table 1. Main characteristics of the 80 HIV-infected MSM at acute HCV infection diagnosis reported by physicians, medical
questionnaire, HEPAIG study, 2006–2007.
Region of care Paris area 48 (60.0)
Age, years 40 (36–44)
Year of HCV diagnosis 2006 41 (51)
2007 39 (49)
Year of HIV diagnosis ,1996 30 (37.5)
1996–1999 14 (17.5)
$2000 36 (45.0)
Time between HIV and HCV diagnosis, years 9 (3–13.5)
HIV clinical stage primary infection 2 (2.5)
asymptomatic 58 (72.5)
symptomatic 12 (15.0)
AIDS-defining illness 8 (10.0)
HIV viral load undetectable
a under HAART 46 (57.5)
detectable without HAART 22 (26.2)
detectable under HAART 10 (12.5)
missing 2 (2.5)
CD4 cell count/mm
3 .500 46 (57.5)
350–500 20 (25.0)
200–349 11 (13.7)
,200 3 (3.8)
Circumstances of HCV diagnosis
b systematic anti-HCV screening 17 (21.2)
increased ALT level 62 (77.5)
at risk behaviour 27 (33.7)
jaundice 9 (11.2)
Concomitant diagnosis of STI yes 29 (36.2)
no 43 (53.8)
missing 8 (10.0)
Acute HCV infection confirmed
c 59 (74.0)
possible
d 16 (20.0)
re-infection
e 5 (6.0)
ALT level, xULN #1 6 (7.5)
.1–,3 10 (12.5)
3–5 14 (17.5)
.5–7 8 (10.0)
.7–10 4 (5.0)
.10 35 (43.7)
not available 3 (3.7)
HCV viral load,log10, IU/mL 5.9(5.1–6.5)
HCV genotype 1 26 (32.5)
3 8 (10.0)
4 44 (55.0)
not available 2 (2.5)
Note. Data are no. (%) of patients or median values (inter-quartile range); MSM, men who have sex with men; HAART, highly active antiretroviral treatment; STI, sexually
transmitted infection; ALT, alanine aminotransferase; ULN, upper limit of normal;
a,50 copies/mL;
bseveral possible answers;
canti-HCV (+) within one year after anti-
HCV (-) or HCV RNA (+) within one year after both documented anti-HCV (-) and HCV RNA (-);
dHCV RNA (+) either: i) within one year after two documented HCV RNA (-),
or, ii) with symptoms of acute hepatitis and ALT level .10xULN within one year after regular controls of normal ALT (other causes excluded);
epossible acute HCV
infection following primary infection with confirmed viral clearance.
doi:10.1371/journal.pone.0029322.t001
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have not been included in the HEPAIG study case definition (of
note also not part of the 2010 European consensus criteria) [20]; ii)
although most of the HIV-infected patients sought care at least
once a year for follow-up medical care in hospital department, we
may have missed cases who did not.
At risk exposures
Following the first reports suggesting possible sexual transmis-
sion of HCV through traumatic sexual practices in HIV-positive
MSM without exposure to injecting drug use [5,10], two case
control studies including HIV-positive MSM patients with a
diagnosis of acute HCV infection specifically exploring sexual
practices have so far been published [3,21]: Danta et al. recruited
patients who had been diagnosed between 1999 and 2005 and
suggested that traumatic sexual practices were even riskier in the
context of group sex participation. As HCV RNA has been
detected in semen and more often in the semen of HIV-infected
men [22], they suggested that mucosal traumatic sexual practices
could favor HCV transmission; Schmidt et al. recruited HIV-
Table 2. Possible HCV exposures and sexually transmitted infections in the year preceding acute HCV infection diagnosis in the 80
HIV-infected MSM, medical questionnaire, HEPAIG study, 2006-2007.
n( % )
Possible exposures to HCV
* Occupational exposure 1 (1.3)
Tattoo/piercing 3 (3.8)
Mesotherapy, acupuncture, varicose vein sclerotherapy 3 (3.8)
Surgery, digestive endoscopy 11 (13.7)
Snorting drug use 21 (26.3)
Injecting drug use 0
Sexually transmitted infection* Syphilis 34 (42.5)
Chlamydia rectal infection 14 (17.5)
Genital herpes 5 (6.3)
Gonorrhoea 4 (5.0)
Anal HPV infection 2 (2.5)
Note. MSM, men who have sex with men; HPV, Human Papilloma virus; *several possible answers.
doi:10.1371/journal.pone.0029322.t002
Table 3. HIV and HCV serologic status of sexual male partners and sexual practices with regular and casual partners in the six
months before acute HCV infection diagnosis in HIV-infected men who have sex with men (self-administered questionnaires,
HEPAIG study, 2006–2007).
Regular sexual partners Casual sexual partners
n=27 n=49
HIV serologic status positive 20 (74.0) 40 (81.6)
negative 7 (26.0) -
unknown 0 9 (18.4)
HCV serologic status positive 9 (33.3) 3 (6.1)
negative 14 (51.9) -
unknown 4 (14.8) 46 (93.9)
Sexual practices insertive anal sex 19 (70.4) 42 (85.7)
unprotected 18 (94.7) 36 (85.6)
receptive anal sex 25 (92.6) 48 (98.0)
unprotected 24 (96.0) 43 (89.6)
fisting 15 (55.6) 35 (71.4)
unprotected 10 (66.7) 20 (57.1)
BDSM
never 12 (44.4) 23 (46.9)
rarely 8 (29.6) 18 (36.7)
often 7 (25.9) 8 (16.3)
Bleeding during sexual practices 15 (55.6) 23 (46.9)
Note. Data are no (%) of patients; BDSM, bondage, discipline, sadism, masochism.
doi:10.1371/journal.pone.0029322.t003
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2000 and identified risk patterns including fisting, rectal trauma
with bleeding, group sex and snorting drugs. The HEPAIG MSM
had different possible routes of HCV transmission during sex in
the six months before HCV diagnosis: more than one third
reported sniffing cocaine with possible sharing of contaminated
straws [23,24], and one of them also reported injecting cocaine; a
quarter of those who sniffed cocaine also reported intra-rectal use
that may contribute to mucosal damage; over half of the MSM
had STI including rectal ulcerative infections [5] and reported
BDSM that could lead to exposure to bleeding caused by intimate
partner traumatic practices [25]; finally, the use of recreational
drugs during sex (reported by more than two thirds of the
HEPAIG MSM) that has effects such as disinhibition and
unawareness could allow traumatic practices as reflected by the
high proportion of MSM (nearly 48%) reporting bleeding
experiences.
The HEPAIG study design did not include any control group.
Indeed, there was a need for greater insights into potential HCV
at-risk practices in the presumed contamination period that could
be achieved through a very detailed self-administered question-
naire (at least one hour to complete), we were concerned by the
likelihood of a high proportion of control patients who would
decline their participation, thus introducing bias in our results. It
was also essential to explore potential exposures in the presumed
period of contamination among the MSM population not
recruited through specific sites likely to be related to potential
exposures (e.g. STI clinics) and on nationwide basis.
We compared the HEPAIG MSM to the HIV-infected
participants to the large ‘‘Net Gay Barome `tre’’ survey conducted
via French websites for men as the HEPAIG MSM also sought sex
partners on line [26]. The HEPAIG MSM had more sexual
partners, more often practiced fisting (71.6% versus 46%) and
BDSM (53% versus 27%), had more frequent unprotected anal
sex (90% versus 73%) and more often took GHB (47% versus
25%) and ketamine (21% versus 8.3%).
Phylogenetic analysis
In contrast with the recent cases of acute sexually transmitted
HCV infection in HIV-infected MSM reported in Australia and
the US, where genotype 1a or 3a were predominant [27,28],
European data on HCV sequencing in HIV-positive MSM
showed the predominance of genotype 4d and evolutionary
analysis suggested the strains introduction from injecting drug
users (IDU) [29]. The HEPAIG sequencing analysis confirmed the
predominance of genotype 4d (with 50%) over two years and,
showed a monophyletic group of 4d sequences clearly distinct
from 4d sequences obtained from injecting drug use population,
and even from French injecting drug users. Interestingly, the
proportion of genotype 1a (43.7%) was also quite high and
increased between 2006 and 2007. Genotype 1a commonly
identified in IDU [30] may have been introduced into the MSM
population through drug use. In the three clusters 1a, we could
identify similar potential exposures to HCV shared between the
MSM and these exposures were related to sexual activity whereas
for cluster 4d in which more patients were included, multiple and
different possible exposures at risk were observed and, none of
them were shared between all of the MSM. Indeed, one of the
limitations of the phylogenetic analysis is that we could not include
all of the patients’ isolates. However, we showed that no difference
in terms of socio-demographics and characteristics of HIV and
HCV infection were found between the MSM who were included
in the phylogenetic analysis and those who were not.
Reinfection
Among the HEPAIG MSM, we documented five cases of HCV
re-infection, three of them after sustained virologic response to
treatment. Few cases of HCV re-infection in HIV-positive MSM
have been reported so far [31,32] until recent data from the
Netherlands demonstrating a high incidence rate of HCV re-
infection among HIV-infected previously treated for primary
HCV infection [33]. However, most of the first report of re-
infections were documented in HIV-negative IDU after treatment
or spontaneous clearance [34,35]. Spontaneous HCV clearance is
less likely to occur in HIV-infected patients (10 to 15%) [19,36]
than in HIV-negative IDU (25%) [37], as HIV affects the immune
responses to HCV [38]. Also, the opportunity for HCV exposure
may be low in comparison to IDU: at risk practices involve less
frequent exposure to blood than sharing syringes/injection
paraphernalia; HCV prevalence is lower in HIV-positive MSM
(3–6%) than in IDU (75–90%) [1,39] although the true figure in
the specific core group of HIV-positive MSM engaged in
traumatic sexual practices and recreational drugs use during sex
may be higher than in the overall population of HIV-positive
MSM.
The HEPAIG MSM were possibly unaware of their own risk-
taking towards HCV infection, even though they were probably
well-informed on risks of STI through unprotected sexual practices
and of HCV transmission through injecting drug use.
Table 4. Drugs consumptions in the six months before acute
HCV infection diagnosis in the 53 HIV-infected MSM with self-
administered questionnaire, HEPAIG study, 2006–2007.
Psychoactive treatment
a no 23 (43.4)
yes 28 (52.8)
not available 2 (3.8)
Drug use during sex
b Amyl nitrite 47 (88.7)
regular use
c 29 (61.7)
Marijuana 22 (41.5)
regular use 11 (50.0)
Ecstasy 21 (39.6)
regular use 4 (19.0)
Cocaine 21 (39.6)
regular use 6 (28.6)
Intra-rectal use 5 (23.8)
injecting use 1 (4.8)
Heroin 0
Crystal meth/speed/MDA/other
methamphetamines
7 (13.2)
regular use 1 (14.3)
Intra-rectal use 2 (28.6)
Injecting use 0
GHB 25 (47.2)
regular use 8 (32.0)
Ketamine 11 (20.7)
regular use 1 (9.1)
Note. Data are no. (%) of patients. MDA, 3–4 methylene dioxy-amphetamine;
GHB, gamma hydroxy butyric acid;
aincluding anxiolytic, hypnotic or
antidepressant;
bseveral possible answers;
cuse at least 10 times during the six-
month period
doi:10.1371/journal.pone.0029322.t004
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PLoS ONE | www.plosone.org 7 December 2011 | Volume 6 | Issue 12 | e29322HEPAIG provided nationwide estimates of incidence of HCV
infection among the HIV-infected MSM population, together with
phylogenetic analysis of the HCV strains transmitted and
comprehensive description of sexual behaviours in the six months
preceding acute HCV infection. It emphasizes the role of
widespread use of recreational drugs during sex and, engagement
in rough sexual practices in the transmission of HCV. Risk of re-
infection is also of concern. Thus, in addition to routine and
repeated screening for HCV in HIV-infected MSM, there is a
need to adapt strategies to prevent HCV transmission and this
could be achieved in a joint effort by health care professionals,
public health professionals with advocacy groups.
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